Abstract We analyzed the sequence variation in the coding exons of PAX6 in eight unrelated south Indian pedigrees with one aniridic individual in each family. Mutations were detected by PCR, SSCP and allele-specific cloning followed by sequencing. Here we report two de novo deletion mutations, c.537delA (codon 59) and c.728del14 (codon 122), in the paired domain of PAX6. These deletions probably represent null or hypomorphic alleles consistent with PAX6 haploinsufficiency as the underlying genetic factor of aniridia.
Introduction
Aniridia is a panocular human eye malformation caused by heterozygous null mutations within the paired box transcription factor gene PAX6 (Ton et al. 1991; Glaser et al. 1992) . Loss-of-function mutations in PAX6 are responsible for several naturally occurring ocular phenotypes characterized by iris hypoplasia, cataract and corneal opacity in association with other ocular disorders like congenital ptosis, nystagmus, strabismus, and glaucoma (Nelson et al. 1984; Glaser et al. 1992 Glaser et al. , 1994 Hanson et al. 1993) . The gene has both homeobox and paired box motifs characteristic of transcriptional regulators and has multiple roles in eye development and maintenance. Aniridia is most simply explained by the reduction in PAX6 activity at the cellular level: most described mutations are predicted to truncate the polypeptides through nonsense-mediated mRNA decay (van Heyningen and Williamson 2002) .
In this report, we describe two novel paired box deletions in the PAX6 gene of aniridic patients out of eight pedigrees studied in south India. These deletions result in premature truncation of the polypeptide.
Methods

Clinical description
A total of eight pedigrees with affected probands and 80 controls without any history of eye disease were recruited for this study with informed consent. The Institutional Review Board and Ethics Committee of the Aravind Eye Hospital approved the study and tenets of the Declaration of Helsinki on Human trials were strictly adhered to.
Genomic DNA isolation DNA was isolated from lymphocytes by the salting out method (Miller et al. 1988 ) and suspended in TE buffer (10 mM Tris, 0.1 mM EDTA, pH 8).
PCR-SSCP
Amplification was carried out in a 20-ll reaction containing 100 ng of genomic DNA, 0.5 U of Taq, 2 mM MgCl 2 , 200 lM dNTPs and 100 pM of published primers (Glaser et al. 1992 ) and a touch down PCR program was performed with initial denaturation at 95°C for 9 min followed by 35 cycles of 95°C for 30 s to 62°C (À0.3°C/cycle) for 30 s to 72°C for 2 min. The amplified products were denatured and electrophoresed on a 10% polyacrylamide gel.
TA cloning PCR products of the mutant were cloned into pGEMT vector and sequence confirmation performed, as previously described (Neethirajan et al. 2003) . Allele-specific PCR with repeated sequencing of different clones was performed since direct sequencing of genomic PCR gave superimposed signals. The clones with mutant alleles were selected by performing PCR-SSCP for plasmid DNA from the transformed colonies in comparison with genomic DNA (Fig. 2a) .
Restriction digestion
The PCR products of exon 7 of normal and mutant alleles were digested with 2 U of NheI and analyzed on 2% agarose gel to reconfirm the presence of the variation, which was identified by sequencing.
Results
SSCP analysis of the PAX6 gene in cases affected by aniridia showed mobility shift compared with wild type (Fig. 1a,d ). The allele-specific clones, which showed the same pattern as that of genomic DNA with the mutant allele in the polyacrylamide gel, help us to pickup the exact clone for sequencing (Fig. 2a) . The plasmid-based sequencing revealed two novel mutations in the PAX6 gene c.537delA in exon 6 (Fig. 1b,c) of proband from family AJA and c.728del14 in exon 7 (Fig. 1e,f) of proband from family MAH. These mutations were completely absent in the normal controls screened. The novel mutant sequences were deposited in GenBank (accession no. AY485787, AY485788). The 14-bp deletion in exon 7 (c.728del14) resulted in the loss of NheI restriction site (Fig. 2b) and cosegregated with the disease-causing phenotype.
Discussion
Deletion of single and multiple base-pair changes found in these two cases of sporadic aniridia were within the paired box of the PAX6 gene and have not previously been reported in the Human PAX6 Allelic Variant Database (http://pax6.hgu.mrc.ac.uk). The proband with c.537delA showed corneal pannus with corneal haze and associated upward subluxation of clear lens associated with aniridia. The other proband with c.728del14 had corneal edema and upward subluxation of cataractous lens with total aniridia. Family relationships have not been confirmed by genetic fingerprinting, but we assume that both mutations are sporadic. The deletion (c.537delA) is predicted to disrupt codon 59 (arginine) causing a frame-shift mutation that leads to a stop codon within the paired box of PAX6 (Fig. 2c) . The amino acid sequence of the c.728del14 mutant polypeptide is altered from the serine residue (Fig. 2c) .
Fourteen base-pair deletions are rare events in the PAX6 gene. Previously, other studies reported a 14-bp deletion, c.709del14, and a 6-bp deletion, c.719del6, in the paired box of PAX6 correlating with the pathogenicity of aniridia (Vincent et al. 2002; Wolf et al. 1998 ). Both mutations resulted in termination of the polypeptide chain in the paired domain and hence truncation of the PAX6 protein. In summary, novel deletions within the paired box region of PAX6 were observed in two families out of the eight south Indian pedigrees. The deletions are predicted to lead to premature polypeptide chain termination with disruption of DNA binding activity, consistent with the conventional aniridia phenotype being caused by haploinsufficiency at the PAX6 locus. It is likely that the mutant alleles produce polypeptides that are subjected to nonsense-mediated decay and are therefore null (Byers 2002; Neethirajan et al. 2003) . In contrast, we could not detect any mutations in six affected families, where mutations might have occurred in one of the cis regulatory regions. 
